From lowdosenaltrexone.org
From tnibiotech.com
Dr. Henry “Skip” Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
As of October 2012:
TNI Acquires Bihari’s Patents; Phase III Trial Planned. Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, recently announced that his company has acquired all of Dr. Bernard Bihari's use-patents for low dose naltrexone. This will enable TNI to proceed with its plans for a phase III clinical trial within the next 12 months, as well as plans to manufacture and sell the drug. Dr. Plotnikoff, quoted on the TNI BioTech website, said:
“I worked with Dr. Bernard Bihari for many years. I believe acquiring all of the technology of Dr. Bihari will allow the company, we hope, to move forward to Phase III clinical trials in both the United States and Africa within the next 12 months. In our opinion, LDN holds great promise for the millions of people worldwide with autoimmune diseases or central nervous system disorders or who face a deadly cancer. It could prove to be the first low-cost, easy to administer, and side-effect-free therapy for cancer, HIV/AIDS, MS and Crohn’s disease.”TNI BioTech has begun construction of a large pharmaceutical plant in Managua, Nicaragua for the production of LDN, under the trade name of IRT-103. It expects to be in operation by the end of this month and it is said to be capable of manufacturing well over one billion of the capsules annually. According to their website, the goal of TNI BioTech is “to enable mankind...to combat fatal disease by...mobilizing the body’s own immune system using TNI’s patented compound(s)”.
Dr. Plotnikoff, Emeritus Professor of Pharmacology and Psychoneuroimmunology, College of Pharmacy and College of Medicine, at the University of Illinois in Chicago, holds a PhD in Pharmacology. Prior to TNI, Dr. Plotnikoff helped direct research for Abbott Labs.
[Editor's Note: Some readers have expressed concern that the patenting and manufacture of LDN by a pharmaceutical company would increase the price of LDN for all users. Although a manufactured brand would initially have an increased price, it is probable that the price of LDN as an off-label, compounded drug should not be substantially affected. To explain why, later this month we will be posting a new entry on the LDN Editor's Blog.]
From tnibiotech.com
Dr. Henry “Skip” Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer